Skip to content

Therapeutic Effect of Compound Lonicera Japonica Stem Oral Liquid on Endometriosis

Study on the Therapeutic Effect of Compound Lonicera Japonica Oral Liquid on Endometriosis and Its Mechanism in Regulating the Polarization of M1/M2 Macrophages

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001286
Enrollment
Unknown
Registered
2026-05-26
Start date
2025-08-27
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

Hormone group:Take dienogest tablets starting from the first day of menstruation, 2mg per time per day, for a continuous treatment of 6 months.
Compound Lonicera Japonica Vine Oral Liquid Group:The patient takes Compound Lonicera Japonica Vine Oral Liquid, stops taking the medicine during menstruation, and the treatment cycle is 6 months.

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Western medicine diagnostic criteria: Refer to the diagnostic criteria for endometriosis in the "Guidelines for the Diagnosis and Treatment of Endometriosis (Third Edition)"; Traditional Chinese medicine diagnostic criteria: Refer to the diagnostic criteria for endometriosis in the "Revised Research on Clinical Diagnostic and Therapeutic Guidelines for Endometriosis in Traditional Chinese Medicine"; those who meet both Western and Chinese medicine diagnostic criteria; 2. Those with good compliance; 3. Those whose average diameter of ovarian ectopic cysts measured by ultrasound is less than 5cm; 4. Those with complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Those with comorbid mental illnesses and impaired consciousness; 2. Those with comorbid other gynecological diseases; 3. Those with comorbid significant blood or organ dysfunction or abnormal liver and kidney functions.

Design outcomes

Primary

MeasureTime frame
CA125;IL-6;IL-10;ectopic lesion volume;

Secondary

MeasureTime frame
TCM Syndrome Score;VAS(Visual Analogue Scale);CMSS(Cox Menstrual Symptom Scale);

Countries

China

Contacts

Public ContactShi Xiaojun

The First Affiliated Hospital of the First Clinical Medical College of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)

jzyszz233@163.com13857310574

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026